From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.
News|Articles|October 2, 2025
Q3 2025 Recap: Allergy News and Updates
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.
Advertisement
Advertisement
As Q3 closes, HCPLive revisits key advances in
Related to this article
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Advertisement
Advertisement